Abstract
Rifampin, the most potent anti-staphylococcal drug known, was examined for its penetration into the aqueous and vitreous of rabbits after a single oral dose of 150 mg, 300 mg, or 600 mg. Maximum levels after the 150 mg dose were achieved at 4 h and were 4.2 µg/ml in the aqueous and 2.2 µg/ml in the vitreous. After the 300 mg dose, maximum levels were also achieved at 4 h, and were 5.0 µg/ml in the aqueous and 2.6 µg/ml in the vitreous. The 600 mg dose produced maximum levels at 6 h after administration, with 20.0 µg/ml in the aqueous and 15.2 µg/ml in the vitreous. These levels exceed the mimimum inhibitory concentration for many microorganisms and suggest additional investigation into possible applications of systemic rifampin in the prophylaxis and treatment of bacterial endophthalmitis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Archer G, Tenenbaum MJ, Haywood HB (1978) Rifampin therapy ofS. epidermidis: use in infections from indwelling artificial devices. JAMA 240:751–753
Cayley FE, Majumdar SK (1976) Ocular toxicity due to rifampicin. Br Med J 60:199–200
Council on Drugs, American Medical Association (1972) Evaluation of a new antituberculous agent. JAMA 220:414–415
Farr B, Mandell GL (1982) Rifampin. Med Clin North Am 66:157–168
Feldman MF, Moses RA (1977) Corneal penetration of rifampin. Am J Ophthalmol 83:862–865
Furesz S (1970) Chemical and biological properties of rifampicin. Antibiot Chemother 16:316–351
Girling DJ (1976) Ocular toxicity due to rifampicin. Br Med J 60:585
Girling DJ (1977) Adverse reaction to rifampicin in antituberculosis regimens. J Antimicrob Chemother 3:115–132
Grosset J, Leventis SA (1983) Adverse effects of rifampin. Rev Infect Dis [Suppl 3] 5:440–446
Lou P, Kazdan J, Bannatyne RM, Cheung R (1977) Successful treatment ofCandida endophthalmitis with a synergistic combination of Amphotericin B and rifampin. Am J Ophthalmol 83:12–15
Lyons RW (1979) Orange contact lenses from rifampin. N Engl J Med 300:372–373
Mandell GL (1973) Interaction of intraleukocytic bacteria and antibiotics. J Clin Invest 52:1673–1679
Mandell GL, Sande MA (1985) Drugs used in the chemotherapy of tuberculosis and leprosy. In: Goodman A, Gilman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics, 7th edn. Macmillan, New York, pp 1202–1205
McCracken GH, Ginsburg CM, Zwieghaft TC, Clahsen J (1980) Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis againstHaemophilus influenzae type B disease. Pediatrics 66:17–21
Mikuni M, Ohishi M, Suda S, Imai M, Takahashi T (1970) Rifampicin in ophthalmology. Acta Medica et Biologica 18:201–210
Musini A, Cattani F, Bonora F (1970) Emploi de la rifampicine en ophtalmologie. Arch Ophtalmol (Paris) 30:809–816
Naveh Y, Friedman A (1973) Rifampicin therapy in Gramnegative bacteremia in infancy. Arch Dis Child 48:967–969
Norden CW (1975) Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. J Infect Dis 132:493–499
Pavan PR, Brinser JH (1987) Exogenous bacterial endophthalmitis treated without systemic antibiotics. Am J Ophthalmol 104:121–126
Sabath LD, Garner C, Wilcox C (1976) Susceptibility ofStaph. aureus andStaph. epidermidis to 65 antibiotics. Antimicrob Agents Chemother 9:962–969
Sande MA, Scheld WM (1980) Combination antibiotic therapy of bacterial endocarditis. Ann Int Med 92:390–395
Scheld WM, Fletcher DD, Fink FN, Sande MA (1979) Response to therapy in an experimental rabbit model of meningitis due toListeria monocytogenes. J Infect Dis 140:287–294
Smolin G, Okumoto M (1972) Effect of rifampicin onProteus keratitis. Am J Ophthalmol 73:40–45
Stern GA, Okumoto M, Smolin G (1979) Combined Amphotericin B and rifampin treatment of experimentalCandida albicans keratitis. Arch Ophthalmol 97:721–722
Thornsberry C, Baker CN, Kirven LA (1978) In vitro activity of antimicrobial agents on Legionnaire’s disease bacterium. Antimicrob Agents Chemother 13:78–80
Wilkie J, Smolin G, Okumoto M (1972) The effect of rifampicin onPseudomonas keratitis. Can J Ophthalmol 7:309–313
Author information
Authors and Affiliations
Additional information
This work was supported in part by NEI grant EY04474 (Dr. D’Amico)
Rights and permissions
About this article
Cite this article
Wong, K.W., D’Amico, D.J., Oum, B.S. et al. Intraocular penetration of rifampin after oral administration. Graefe’s Arch Clin Exp Ophthalmol 228, 40–43 (1990). https://doi.org/10.1007/BF02764289
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02764289